Can I Take Creatine with Jardiance? A Clinical Review

Jardiance (empagliflozin) is an SGLT2 inhibitor approved by the FDA for type 2 diabetes, heart failure, and chronic kidney disease. Creatine monohydrate is a widely used sports-nutrition supplement, not a drug, that raises muscle phosphocreatine stores. There is no known pharmacokinetic interaction between the two: creatine does not change how empagliflozin is absorbed, metabolized, or cleared, and empagliflozin does not change how creatine is used by muscle. The real issue is interpretive, not chemical. Creatine supplementation is well documented to raise serum creatinine, and because Jardiance's dosing and safety monitoring depend on creatinine-derived eGFR, that rise can make kidney function look worse than it is at the exact moment a clinician is deciding whether to continue or adjust the drug.

The useful question for most patients is not "do these interact" but "will my creatine use be mistaken for kidney injury when my Jardiance labs are checked." That is a solvable problem with the right lab panel and the right conversation with a prescriber, not a reason to avoid either the drug or the supplement by default.

Quick facts

• Empagliflozin (Jardiance) is an SGLT2 inhibitor taken once daily at 10 mg or 25 mg for its approved indications.
• Creatine monohydrate is typically dosed at 3-5 g/day for maintenance, sometimes preceded by a short higher-dose loading period.
• No pharmacokinetic or pharmacodynamic interaction between the two has been established.
• Creatine supplementation is known to raise serum creatinine, which can lower calculated eGFR without reflecting a true decline in kidney function.
• Jardiance's prescribing information sets eGFR thresholds below which the drug is not recommended or requires dose adjustment; these thresholds differ by indication and are subject to label updates, so the current label should be checked directly. (per the current FDA prescribing information, which should be checked directly)
• Cystatin C is a creatinine-independent marker that can help distinguish a lab artifact from a real change in kidney function.

How Jardiance depends on kidney function

Empagliflozin works by blocking the SGLT2 transporter in the kidney's proximal tubule, which reduces glucose reabsorption and increases urinary glucose excretion. It also has hemodynamic effects that lower pressure inside the glomerulus, which is part of why it protects the kidneys over time in trials such as EMPA-KIDNEY, a large randomized trial in patients with chronic kidney disease that found empagliflozin reduced the risk of kidney disease progression or cardiovascular death compared with placebo (NEJM, EMPA-KIDNEY Collaborative Group).

Because the drug's safety monitoring and, in some cases, its dosing are tied to eGFR, and eGFR is calculated from serum creatinine, anything that raises creatinine without a true change in filtration can distort that assessment. That is the mechanism behind the creatine-Jardiance question: it is a lab-interpretation problem sitting on top of a real and well-established drug mechanism.

The FDA label specifies eGFR-based recommendations that vary by indication (glycemic control versus heart failure versus CKD), and these have been updated as new trial data accumulated. Anyone making a dosing decision based on an eGFR near a threshold should confirm the current label language rather than rely on a fixed number quoted secondhand.

What creatine actually does to serum creatinine

Creatine is synthesized endogenously and also taken as a supplement, mostly for its effects on high-intensity exercise performance and lean mass. Most of the body's creatine is stored in skeletal muscle, where some is non-enzymatically converted to creatinine, the same molecule used to estimate kidney function.

Increasing creatine intake increases this conversion, and it is well established across the sports-science literature that creatine supplementation raises serum creatinine, particularly during a higher-dose loading phase. The size of that rise varies by dose, duration, and individual muscle mass, and readers should not treat any single specific percentage or milligram figure as settled without checking the primary trial it comes from; the source studies commonly cited for this effect need to be verified against the original papers rather than taken from secondary summaries.

The distinction that matters clinically is between a creatinine rise that reflects more substrate entering the blood (from muscle creatine turnover) and one that reflects reduced glomerular filtration (true kidney injury). Cystatin C, a filtration marker that is not affected by muscle creatine metabolism, is the standard way to tell these apart when the two markers disagree. A joint task force from the National Kidney Foundation and American Society of Nephrology has described combined creatinine-cystatin C equations as reducing bias in populations where muscle mass or dietary intake affects creatinine, though the exact citation for that report should be confirmed before it is used to support a specific numeric claim.

In people with normal or near-normal kidney function, the available exercise-science literature has generally not shown creatine supplementation to cause genuine kidney damage over periods studied. In people with more advanced chronic kidney disease, controlled trial data are much thinner, and caution with a nephrologist's involvement is reasonable rather than optional.

Is there a real pharmacological interaction?

No pharmacokinetic interaction is known. Empagliflozin is cleared mainly through glucuronidation, not through pathways that creatine is known to affect, and creatine is not described as a substrate or inhibitor of the enzymes involved in empagliflozin's metabolism per its FDA label. Creatine also does not raise blood glucose, does not oppose the glucose-lowering or diuretic mechanisms of empagliflozin, and is not listed as a contraindication or warning on the Jardiance label.

That absence of a direct pharmacological interaction is the reassuring part of the picture. It does not remove the lab-interpretation problem described above, which is the part that actually needs a plan.

A worked example of the interpretive risk

Consider a patient with an eGFR near a threshold that would prompt a Jardiance dose review. If creatine supplementation pushes their measured creatinine up modestly, their calculated eGFR could cross that threshold on paper without any true decline in kidney function. A prescriber unaware of the creatine use could reasonably, but incorrectly, scale back or stop a drug that is actively protecting that patient's heart and kidneys. This is the scenario the monitoring plan below is designed to prevent.

Special situations

Chronic kidney disease. Patients with more advanced CKD are simultaneously the group with the strongest evidence for empagliflozin's protective benefit and the group most vulnerable to a false alarm from creatine-related lab confounding. Nephrology involvement is reasonable before adding creatine at CKD stage 3b or beyond, given the thinner safety data in this population.

Heart failure. Empagliflozin has established mortality and hospitalization benefits in heart failure with reduced and preserved ejection fraction, based on the EMPEROR-Reduced and EMPEROR-Preserved trials (EMPEROR-Reduced, NEJM; EMPEROR-Preserved, NEJM). Creatine's loading phase causes some intracellular water retention, and empagliflozin causes mild osmotic diuresis; these pull in different directions and are not expected to meaningfully interact, but patients on a strict fluid or dry-weight target should mention creatine loading to their cardiology team before starting, since even a modest transient weight change can complicate that monitoring.

Older adults. Lower baseline muscle mass in older adults means baseline creatinine is often already lower than expected for true filtration rate. A given absolute rise in creatinine from creatine supplementation can therefore look proportionally larger and more alarming in an older adult than in a younger one, even when the underlying change in kidney function is the same or smaller. This is a reason for closer lab interpretation, not a reason to avoid creatine outright.

Evidence-status interaction assessment

A practical monitoring plan

Kidney function monitoring is already standard practice for anyone on empagliflozin. Adding creatine does not remove that requirement; it adds a step of interpretation.

Before starting creatine, ask your prescriber to document a baseline that includes serum creatinine and, if available, cystatin C, along with your usual kidney panel. This gives a reference point that is not confounded by the supplement.

After starting creatine, if a follow-up eGFR looks lower than expected, ask whether cystatin C-based eGFR can be checked alongside the creatinine-based value. If the cystatin C-based estimate is stable while the creatinine-based estimate has dropped, the change is most likely a lab artifact from creatine, not true kidney injury, and empagliflozin generally would not need to be adjusted on that basis alone. If both markers have declined together, that is a signal for prompt clinical evaluation rather than reassurance.

Skipping a high-dose loading phase and starting directly at a lower maintenance dose produces a smaller, more gradual rise in creatinine, which is easier to interpret against a baseline. This is a reasonable, low-risk adjustment to discuss with a prescriber rather than a guaranteed solution, since even gradual creatinine increases can still cross a threshold in someone whose eGFR was already borderline.

What to tell your doctor

Bring your creatine use, dose, and brand to every appointment where kidney labs are drawn. A useful way to frame it: "I take creatine monohydrate at this dose. If my creatinine looks worse than expected, can we check cystatin C before changing my Jardiance dose." If your prescriber is unfamiliar with cystatin C-based eGFR, ask for a referral or a nephrology consult rather than accepting a dosing change made on creatinine alone when a supplement is a plausible confounder.

Contact emergency services or urgent care immediately rather than scheduling a routine appointment if you develop signs of serious kidney or metabolic complications while taking empagliflozin, including markedly reduced urine output, new fluid retention, altered mental status, intense nausea with vomiting, or ketoacidosis symptoms (extreme tiredness, stomach pain, shortness of breath). These warning signs cannot be dismissed as effects of empagliflozin and require immediate medical assessment to rule out serious conditions.

Evidence boundary

What is established: empagliflozin and creatine do not share a metabolic pathway, and no pharmacokinetic interaction has been described. Creatine reliably raises serum creatinine. Empagliflozin's monitoring and, for some indications, its dosing are tied to eGFR calculated from creatinine.

What is plausible but not directly documented: that this combination leads in practice to inappropriate dose changes for Jardiance when a prescriber is unaware of a patient's creatine use. This follows logically from the two established facts but has not been specifically studied as a documented clinical problem.

What is not established: the long-term renal safety of creatine supplementation in patients with moderate-to-severe CKD who are also taking an SGLT2 inhibitor, and any precise numeric estimate of how much serum creatinine rises for a given creatine dose in this specific population. Any such number found elsewhere should be checked against its original source before being used for a real dosing or monitoring decision.

References

• The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. nejm.org
• Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced). N Engl J Med. nejm.org
• Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction (EMPEROR-Preserved). N Engl J Med. nejm.org

Specific numeric claims about creatine's effect size on serum creatinine, and any quoted statements attributed to individual clinicians or specific creatine trials in earlier drafts of this material, require verification against their original primary sources before publication. Where verification could not be completed, those claims have been removed or narrowed rather than presented as sourced facts.